Beam Therapeutics Inc
NASDAQ:BEAM 4:00:00 PM EDT
Market Cap (Intraday) | 2.78B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $36.05 |
50-Day MA | $30.98 |
200-Day MA | $27.88 |
Beam Therapeutics Inc Stock, NASDAQ:BEAM
238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016
United States of America
Phone: +1.857.327.8775
Number of Employees: 436
Description
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.